遺伝子検査市場

The secondary research process involved comprehensive analysis of regulatory databases, peer-reviewed medical journals, clinical genomics publications, and authoritative health organizations. Key sources included the US Food & Drug Administration (FDA) - Center for Devices and Radiological Health (CDRH) and In Vitro Diagnostics (IVD) database, Centers for Medicare & Medicaid Services (CMS) - Molecular Diagnostic Services (MolDX) Program and National Coverage Determinations (NCD), National Human Genome Research Institute (NHGRI) - Genome-wide Association Studies Catalog and ClinVar database, Centers for Disease Control and Prevention (CDC) - Office of Genomics and Precision Public Health (OGPPH) and Newborn Screening Technical assistance and Evaluation Program (NewSTEPs), National Institutes of Health (NIH) - Genetic Testing Registry (GTR) and Online Mendelian Inheritance in Man (OMIM), European Medicines Agency (EMA) - Committee for Advanced Therapies (CAT) and In Vitro Diagnostic Medical Devices Regulation (IVDR) database, Concert Genetics - Genetic Testing Claims Database and Test Catalog Database, World Health Organization (WHO) - Human Genomics Programme and International Classification of Diseases (ICD-11) genetic disorder classifications, Eurostat Healthcare Statistics - Medical technology and diagnostic imaging databases, National Center for Biotechnology Information (NCBI/PubMed) - Genetics and genomics literature repositories, American College of Medical Genetics and Genomics (ACMG) - Practice Guidelines and Policy Statements, American Society of Human Genetics (ASHG) - Population screening and research databases, European Society of Human Genetics (ESHG) - Quality guidelines and genetic service registries, National Society of Genetic Counselors (NSGC) - Professional practice survey data, International Society for Prenatal Diagnosis (ISPD) - Prenatal screening guidelines and utilization data, Human Genome Organisation (HUGO) - Global genomic medicine implementation databases, Association for Molecular Pathology (AMP) - Molecular testing standards and economic data, College of American Pathologists (CAP) - Laboratory accreditation and proficiency testing surveys, and national genetic service registries from key markets (UK NHS Genomic Medicine Service, France ANPGM, Germany GBA Innovation Committee). These sources were used to collect procedure volumes, regulatory approval data (510(k), PMA, De Novo pathways), clinical utility studies, newborn screening panel statistics, reimbursement coverage policies (CPT codes, fee schedules), genetic counselor workforce data, and genomic testing technology adoption trends across diagnostic, predictive, carrier, and prenatal testing segments.

Qualitative and quantitative insights were obtained by interviewing supply-side and demand-side stakeholders during the primary research process. The supply-side sources consisted of CEOs, VPs of R&D, Chief Scientific Officers, and regulatory affairs chiefs from molecular diagnostics companies, genetic testing laboratories, bioinformatics software providers, and next-generation sequencing platform manufacturers. Procurement managers from hospital systems and academic medical centers, payor policy specialists from commercial insurers and Medicare Advantage plans, maternal-fetal medicine specialists, oncology precision medicine leads, genetic counselors, laboratory directors of molecular pathology, and board-certified clinical geneticists comprised demand-side sources. The primary research validated test volume assumptions, confirmed the utilization of CLIA laboratory capacity, verified pricing dynamics across direct-to-consumer and clinical channels, and gathered insights on pipeline development timelines for whole genome sequencing expansion, pharmacogenomics integration, and AI-enabled variant interpretation.

Primary Respondent Breakdown:

By Designation: C-level Primaries (32%), Director Level (30%), Others (38%)

By Region: North America (38%), Europe (25%), Asia-Pacific (28%), Rest of World (9%)

Global market valuation was derived through revenue mapping and test volume analysis. The methodology included:

Identification of 55+ key manufacturers and service providers across North America, Europe, Asia-Pacific, and Latin America covering sequencing platforms, consumables/reagents, testing services, and bioinformatics interpretation

Product and service mapping across single gene tests, multi-gene panels (hereditary cancer, cardiovascular, neurological), whole exome sequencing, whole genome sequencing, non-invasive prenatal testing (NIPT), and pharmacogenomic testing categories

Analysis of reported and modeled annual revenues specific to genetic testing portfolios and laboratory service operations

Coverage of manufacturers and laboratory service providers representing 75-80% of global market share in 2024

Extrapolation using bottom-up (test volume × average selling price by country by test type: newborn screening volumes from national programs, prenatal testing adoption rates, oncology companion diagnostic penetration) and top-down (manufacturer revenue validation and NGS platform installation base analysis) approaches to derive segment-specific valuations

Integration of reimbursement data from CMS fee schedules (CPT 81400-81479 codes), commercial payor coverage policies, and out-of-pocket direct-to-consumer pricing to model average revenue per test (ARPT) across clinical and homecare settings

Validation against public health newborn screening databases (approximately 4 million annual births screened in US alone) and global prenatal cfDNA testing volumes to anchor market sizing in verifiable procedure statistics